T cell receptor delta variable 2 (TRDV2) (TCR Vδ2)

The T cell receptor delta variable 2 (TRDV2) chain is a defining component of the Vγ9Vδ2 T cell receptor complex, which is expressed by the most abundant subset of gamma delta T cells in human peripheral blood (Source: UniProt P0CF51). These Vγ9Vδ2 T cells function as a bridge between innate and adaptive immunity, recognizing non-peptide phosphoantigens in a Major Histocompatibility Complex (MHC)-independent manner through interactions with butyrophilin proteins BTN3A1 and BTN2A1 (Source: Nature Reviews Immunology, 2013). In oncology, the Vδ2 chain is a high-priority therapeutic target for bispecific antibodies, often referred to as Gammabodies, which cross-link the T cell to tumor-associated antigens to induce potent, localized cytotoxicity (Source: LAVA Therapeutics, 2024). This targeting strategy leverages the natural anti-tumor properties of Vγ9Vδ2 T cells and their ability to infiltrate solid tumors without the risk of graft-versus-host disease. Clinical applications focus on activating these cells to treat various malignancies, including prostate cancer and hematological diseases, while managing potential side effects like cytokine release syndrome (Source: Frontiers in Immunology, 2020).

Other names

TRDV2T-cell receptor delta chain variable region 2Vdelta2Vd2TCRVd2

Bispecific engagement of the Vδ2 TCR chain to cross-link Vγ9Vδ2 T cells with tumor cells, leading to T-cell activation, degranulation, and tumor cell apoptosis (Source: LAVA Therapeutics, 2024). Agonistic small molecules or phosphoantigens can also trigger conformational changes in the TCR complex to initiate activation (Source: Nature Reviews Immunology, 2013).